APLM

Apollomics Inc.

Nasdaq · Pharmaceutical Preparations · CIK 0001944885
$14.31 +4.42% $31.4M
High Impact Filing (7/10)
Vol
Market Cap$31.4M
Cap SizeNano Cap
SEC Reports1
Exchange Nasdaq·Sector Pharmaceutical Preparations·CIK 0001944885·Prev Close $13.70

Recent Activity

May 17, 2026 Insider
Huang Ya-Chi acquired via exercise 500 shares
Director
Apr 27, 2026 SEC
Apollomics reported its 2025 full-year financial results, posting $8.5M in revenue from a licensing deal with LaunXP, a
PRESS-RELEASE — Impact 7/10
Apr 27, 2026 earnings
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
<p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/
Mar 31, 2026 Insider
LIN PETER KUAN-HOW surrendered for taxes 3,582 shares
Chief Financial Officer @ $15.85 ($56.8K)

Analyst Ratings

Historical distribution86% buy · 7 analysts · last covering-analyst action May 2024
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
DateFirmActionRating
May 8, 2024 HC Wainwright & Co. MAINTAIN Buy → Buy
Apr 1, 2024 EF Hutton MAINTAIN Buy → Buy
Apr 1, 2024 HC Wainwright & Co. MAINTAIN Buy → Buy
Nov 20, 2023 HC Wainwright & Co. REITERATE Buy → Buy
Oct 3, 2023 HC Wainwright & Co. MAINTAIN Buy → Buy

Recent Insider Trades

DateInsiderTypeValue
May 17, 2026Huang Ya-ChiM$0.00
Mar 31, 2026LIN PETERF$56.8K

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

2 unique insiders with 2 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 17, 2026Huang Ya-ChiDirectorEXERCISE500
Mar 31, 2026LIN PETER KUAN-HOWChief Financial OfficerTAX W/H3,582$15.85$56.8K
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action May 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2024-09-30
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
2024-12-31
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 8, 2024 HC Wainwright & Co. MAINTAIN Buy Buy
Apr 1, 2024 EF Hutton MAINTAIN Buy Buy
Apr 1, 2024 HC Wainwright & Co. MAINTAIN Buy Buy
Nov 20, 2023 HC Wainwright & Co. REITERATE Buy Buy
Oct 3, 2023 HC Wainwright & Co. MAINTAIN Buy Buy
Jun 5, 2023 HC Wainwright & Co. REITERATE Buy Buy
Jun 1, 2023 HC Wainwright & Co. INITIATE Buy
Apr 25, 2023 EF Hutton INITIATE Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Dec 1, 20242410086%
Nov 1, 20242410086%
Oct 1, 20242410086%
Sep 1, 20242410086%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Apr 27, 2026
earnings
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
<p>FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=izxkXWzOHUxYAEZ4qIXzYKNJN17xHzjbedxZO